Please use this identifier to cite or link to this item: http://hdl.handle.net/11455/97729
標題: 自噬作用對非小細胞肺癌抗藥性之調控
Autophagy-mediated drug resistance of non-small cell Lung cancer
作者: 盧奕瑄
Yi-Hsuan Lu
關鍵字: 自噬作用
抗藥性
ROSI
Cisplatin
PPAR-γ
石蓮花
非小細胞肺癌
Autophagy
Drug resistance
Rosiglitazone
Cisplatin
PPAR-γ
Graptopetalum paraguayense
NSCLC
引用: 一、中文部分 1. 洪躍聞 (2014) 過氧化物增殖活化受體誘導之脂質小滴對非小細胞肺癌發炎活性之調控。國立中興大學,生命科學研究所,碩士論文。 2. 黃至靚 (2018) 脂質小滴對非小細胞肺癌(H460)存活的保護機制探討。國立中興大學,生命科學研究所,碩士論文。 3. 鄭幼鈞 (2007) 非小細胞肺癌(H460)抗藥性之機轉探討:XIAP蛋白之參與。國立中興大學,生命科學研究所,碩士論文。 4. 黃思寧 (2018) 環指蛋白146對parthanatos的抑制可降低順鉑對非小細胞肺癌的傷害。國立中興大學,生命科學研究所,碩士論文。 二、西文部分 [1-96] 1. Aga T, Endo K, Tsuji A, Aga M, Moriyama-Kita M, et al. Inhibition of autophagy by chloroquine makes chemotherapy in nasopharyngeal carcinoma more efficient. Auris Nasus Larynx. 2. Al-Alem L, Southard RC, Kilgore MW, Curry TE (2011) Specific thiazolidinediones inhibit ovarian cancer cell line proliferation and cause cell cycle arrest in a PPARγ independent manner. PloS one 6: e16179-e16179. 3. Andrews PA, Velury S, Mann SC, Howell SB (1988) <em>cis</em>-Diamminedichloroplatinum(II) Accumulation in Sensitive and Resistant Human Ovarian Carcinoma Cells. Cancer Research 48: 68. 4. Avruch J, Long X, Lin Y, Ortiz-Vega S, Rapley J, et al. (2009) Activation of mTORC1 in two steps: Rheb-GTP activation of catalytic function and increased binding of substrates to raptor<sup>1</sup>. Biochemical Society Transactions 37: 223. 5. Björn Stork SA, Antje S. Löffler and Sebastian Wesselborg (2012) Regulation of Autophagy by Protein Phosphorylation. Protein Phosphorylation in Human Health. 6. Chen H-C, Hsu H-T, Weng J-W, Chang Y-F, Hsia C-Y, et al. (2016) Combined effect of honokiol and rosiglitazone on cell growth inhibition through enhanced G0/G1 phase arrest in hepatoma cells. Journal of the Chinese Medical Association 79: 415-421. 7. Chen J, Zhang L, Zhou H, Wang W, Luo Y, et al. (2018) Inhibition of autophagy promotes cisplatin-induced apoptotic cell death through Atg5 and Beclin 1 in A549 human lung cancer cells. 8. Chen J-L, Lin HH, Kim K-J, Lin A, Forman HJ, et al. (2008) Novel Roles for Protein Kinase Cδ-dependent Signaling Pathways in Acute Hypoxic Stress-induced Autophagy. Journal of Biological Chemistry 283: 34432-34444. 9. Chen J-L, Lin HH, Kim K-J, Lin A, Ou JHJ, et al. (2009) PKC delta signaling: a dual role in regulating hypoxic stress-induced autophagy and apoptosis. Autophagy 5: 244-246. 10. Chen L-M, Song T-J, Xiao J-H, Huang Z-H, Li Y, et al. (2017) Tripchlorolide induces autophagy in lung cancer cells by inhibiting the PI3K/AKT/mTOR pathway and improves cisplatin sensitivity in A549/DDP cells. Oncotarget. pp. 63911-63922. 11. Chen S-J, Chung J-G, Chung Y-C, Chou S-T (2008) In vitro Antioxidant and Antiproliferative Activity of the Stem Extracts from Graptopetalum paraguayense. The American Journal of Chinese Medicine 36: 369-383. 12. Chen S-J, Yen C-H, Liu J-T, Tseng Y-F, Lin P-T (2016) Anti-inflammatory effect of water extracts of Graptopetalum paraguayense supplementation in subjects with metabolic syndrome: a preliminary study. Journal of the Science of Food and Agriculture 96: 1772-1776. 13. Cheng Y-J, Jiang H-S, Hsu S-L, Lin L-C, Wu C-L, et al. (2010) XIAP-mediated protection of H460 lung cancer cells against cisplatin. European Journal of Pharmacology 627: 75-84. 14. Cole SP, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, et al. (1992) Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 258: 1650. 15. Dasari S, Bernard Tchounwou P (2014) Cisplatin in cancer therapy: Molecular mechanisms of action. European Journal of Pharmacology 740: 364-378. 16. De Stefani E, Deneo-Pellegrini H, Boffetta P, Brennan P, Ronco A, et al. (2004) Cigarette smoking and risk of large cell carcinoma of the lung: a case-control study in Uruguay. Lung Cancer 43: 267-274. 17. Debrock G, Vanhentenrijk V, Sciot R, Debiec-Rychter M, Oyen R, et al. (2003) A phase II trial with rosiglitazone in liposarcoma patients. British Journal Of Cancer 89: 1409. 18. Di Bartolomeo S, Corazzari M, Nazio F, Oliverio S, Lisi G, et al. (2010) The dynamic interaction of AMBRA1 with the dynein motor complex regulates mammalian autophagy. The Journal of Cell Biology 191: 155. 19. Diamond GA, Bax L, Kaul S (2007) UNcertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death. Annals of Internal Medicine 147: 578-581. 20. Egan DF, Chun MGH, Vamos M, Zou H, Rong J, et al. (2015) Small Molecule Inhibition of the Autophagy Kinase ULK1 and Identification of ULK1 Substrates. Molecular cell 59: 285-297. 21. Erazo T, Lorente M, López-Plana A, Muñoz-Guardiola P, Fernández-Nogueira P, et al. (2016) The New Antitumor Drug ABTL0812 Inhibits the Akt/mTORC1 Axis by Upregulating Tribbles-3 Pseudokinase. Clinical Cancer Research 22: 2508. 22. Esteva FJ, Moulder SL, Gonzalez-Angulo AM, Ensor J, Murray JL, et al. (2013) Phase I trial of exemestane in combination with metformin and rosiglitazone in nondiabetic obese postmenopausal women with hormone receptor-positive metastatic breast cancer. Cancer chemotherapy and pharmacology 71: 63-72. 23. Fimia GM, Di Bartolomeo S, Piacentini M, Cecconi F (2011) Unleashing the Ambra1-Beclin 1 complex from dynein chains: Ulk1 sets Ambra1 free to induce autophagy. 115-117 p. 24. Foo J, Michor F (2014) Evolution of acquired resistance to anti-cancer therapy. Journal of theoretical biology 355: 10-20. 25. Fujiwara N, Usui T, Ohama T, Sato K (2016) Regulation of Beclin 1 Protein Phosphorylation and Autophagy by Protein Phosphatase 2A (PP2A) and Death-associated Protein Kinase 3 (DAPK3). The Journal of biological chemistry 291: 10858-10866. 26. Green Douglas R, Levine B (2014) To Be or Not to Be? How Selective Autophagy and Cell Death Govern Cell Fate. Cell 157: 65-75. 27. Gu R, Zhang M, Meng H, Xu D, Xie Y (2018) Gallic acid targets acute myeloid leukemia via Akt/mTOR-dependent mitochondrial respiration inhibition. Biomedicine & Pharmacotherapy 105: 491-497. 28. Hsu H-Y, Lin T-Y, Hu C-H, Shu DTF, Lu M-K (2018) Fucoidan upregulates TLR4/CHOP-mediated caspase-3 and PARP activation to enhance cisplatin-induced cytotoxicity in human lung cancer cells. Cancer Letters 432: 112-120. 29. Huang J, Manning BD (2009) A complex interplay between Akt, TSC2 and the two mTOR complexes. Biochemical Society transactions 37: 217-222. 30. Hughes TS, Giri PK, de Vera IMS, Marciano DP, Kuruvilla DS, et al. (2014) An alternate binding site for PPARγ ligands. Nature communications 5: 3571-3571. 31. Inoki K, Li Y, Zhu T, Wu J, Guan K-L (2002) TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nature Cell Biology 4: 648. 32. J. Khandekar M, Banks A, Laznik-Bogoslavski D, White J, Choi JH, et al. (2018) Noncanonical agonist PPARγ ligands modulate the response to DNA damage and sensitize cancer cells to cytotoxic chemotherapy. 201717776 p. 33. Jacobsen K, Bertran-Alamillo J, Molina MA, Teixidó C, Karachaliou N, et al. (2017) Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer. Nature Communications 8: 410. 34. Jiang Y-Q, Zhou Z-X, Ji Y-L (2014) Suppression of EGFR-STAT3 signaling inhibits tumorigenesis in a lung cancer cell line. International journal of clinical and experimental medicine 7: 2096-2099. 35. Kaliappan A, Dennis PB (2009) A novel, human Atg13 binding protein, Atg101, interacts with ULK1 and is essential for macroautophagy AU - Mercer, Carol A. Autophagy 5: 649-662. 36. Kapuscinski J (2009) DAPI: a DNA-specific fluorescent probe. 220-233 p. 37. Kartalou M, Essigmann JM (2001) Mechanisms of resistance to cisplatin. Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis 478: 23-43. 38. Kebebew E, Peng M, Reiff E, Treseler P, Woeber KA, et al. (2006) A phase II trial of rosiglitazone in patients with thyroglobulin-positive and radioiodine-negative differentiated thyroid cancer. Surgery 140: 960-967. 39. Lee J, Sohn EJ, Yoon S, Won G, Kim CG, et al. (2017) Activation of JNK and IRE1 is critically involved in tanshinone I-induced p62 dependent autophagy in malignant pleural mesothelioma cells: implication of p62 UBA domain. Oncotarget 8: 25032-25045. 40. Levine B, Deretic V (2007) Unveiling the roles of autophagy in innate and adaptive immunity. Nature Reviews Immunology 7: 767. 41. Li Y-J, Lei Y-H, Yao N, Wang C-R, Hu N, et al. (2017) Autophagy and multidrug resistance in cancer. Chinese journal of cancer 36: 52-52. 42. Liao C-C, Chen S-C, Huang H-P, Wang C-J (2018) Gallic acid inhibits bladder cancer cell proliferation and migration via regulating fatty acid synthase (FAS). Journal of Food and Drug Analysis 26: 620-627. 43. Lin C-F, Young K-C, Bai C-H, Yu B-C, Ma C-T, et al. (2014) Rosiglitazone Regulates Anti-Inflammation and Growth Inhibition via PTEN. BioMed Research International 2014: 14. 44. Lin J-F, Lin Y-C, Tsai T-F, Chen H-E, Chou K-Y, et al. (2017) Cisplatin induces protective autophagy through activation of BECN1 in human bladder cancer cells. Drug design, development and therapy 11: 1517-1533. 45. Lin L-C, Hsu S-L, Wu C-L, Hsueh C-M (2014) TGFβ can stimulate the p38/β-catenin/PPARγ signaling pathway to promote the EMT, invasion and migration of non-small cell lung cancer (H460 cells). 46. Lin L-C, Hsu S-L, Wu C-L, Liu W-C, Hsueh C-M (2011) Peroxisome proliferator-activated receptor γ (PPARγ) plays a critical role in the development of TGFβ resistance of H460 cell. Cellular Signalling 23: 1640-1650. 47. Lippert TH, Ruoff H-J, Volm M (2008) Intrinsic and Acquired Drug Resistance in Malignant Tumors. Arzneimittelforschung 58: 261-264. 48. Liu H-Y, Peng H-Y, Hsu S-L, Jong T-T, Chou S-T (2015) Chemical characterization and antioxidative activity of four 3-hydroxyl-3-methylglutaroyl (HMG)-substituted flavonoid glycosides from Graptopetalum paraguayense E. Walther. Botanical Studies 56: 8. 49. Luo S, Rubinsztein DC (2007) Atg5 and Bcl-2 provide novel insights into the interplay between apoptosis and autophagy. Cell Death And Differentiation 14: 1247. 50. Macciò A, Madeddu C (2013) Cisplatin: an old drug with a newfound efficacy – from mechanisms of action to cytotoxicity. Expert Opinion on Pharmacotherapy 14: 1839-1857. 51. Marinkovi, #x, M, #x, prung M, et al. (2018) Autophagy Modulation in Cancer: Current Knowledge on Action and Therapy. Oxidative Medicine and Cellular Longevity 2018: 18. 52. Matsumoto M, Nakajima W, Seike M, Gemma A, Tanaka N (2016) Cisplatin-induced apoptosis in non-small-cell lung cancer cells is dependent on Bax- and Bak-induction pathway and synergistically activated by BH3-mimetic ABT-263 in p53 wild-type and mutant cells. Biochemical and Biophysical Research Communications 473: 490-496. 53. Moscat J, Diaz-Meco MT (2012) p62: a versatile multitasker takes on cancer. Trends in Biochemical Sciences 37: 230-236. 54. Mukhopadhyay S, Frias MA, Chatterjee A, Yellen P, Foster DA (2016) The Enigma of Rapamycin Dosage. Molecular Cancer Therapeutics 15: 347. 55. Nam B, Rho JK, Shin D-M, Son J (2016) Gallic acid induces apoptosis in EGFR-mutant non-small cell lung cancers by accelerating EGFR turnover. Bioorganic & Medicinal Chemistry Letters 26: 4571-4575. 56. Nazim UM, Moon J-H, Lee Y-J, Seol J-W, Park S-Y (2017) PPARγ activation by troglitazone enhances human lung cancer cells to TRAIL-induced apoptosis via autophagy flux. Oncotarget 8: 26819-26831. 57. O'Donovan TR, O'Sullivan GC, McKenna SL (2011) Induction of autophagy by drug-resistant esophageal cancer cells promotes their survival and recovery following treatment with chemotherapeutics. Autophagy 7: 509-524. 58. Peters JM, Shah YM, Gonzalez FJ (2012) The role of peroxisome proliferator-activated receptors in carcinogenesis and chemoprevention. Nature reviews Cancer 12: 181-195. 59. Randall-Demllo S, Chieppa M, Eri R (2013) Intestinal epithelium and autophagy: partners in gut homeostasis. Frontiers in immunology 4: 301-301. 60. Ren J-H, He W-S, Nong L, Zhu Q-Y, Hu K, et al. (2010) Acquired Cisplatin Resistance in Human Lung Adenocarcinoma Cells Is Associated with Enhanced Autophagy. Cancer Biotherapy and Radiopharmaceuticals 25: 75-80. 61. Rovito D, Giordano C, Plastina P, Barone I, De Amicis F, et al. (2015) Omega-3 DHA- and EPA–dopamine conjugates induce PPARγ-dependent breast cancer cell death through autophagy and apoptosis. Biochimica et Biophysica Acta (BBA) - General Subjects 1850: 2185-2195. 62. Sato K, Sugawara A, Kudo M, Uruno A, Ito S, et al. (2004) <B>Expression of Peroxisome Proliferator-Activated Receptor Isoform Proteins in the Rat Kidney</B>. Hypertension Research 27: 417-425. 63. Seargent JM, Yates EA, Gill JH (2004) GW9662, a potent antagonist of PPARgamma, inhibits growth of breast tumour cells and promotes the anticancer effects of the PPARgamma agonist rosiglitazone, independently of PPARgamma activation. British journal of pharmacology 143: 933-937. 64. Senthebane DA, Rowe A, Thomford NE, Shipanga H, Munro D, et al. (2017) The Role of Tumor Microenvironment in Chemoresistance: To Survive, Keep Your Enemies Closer. International Journal of Molecular Sciences 18. 65. Shen D-W, Pouliot LM, Hall MD, Gottesman MM (2012) Cisplatin resistance: a cellular self-defense mechanism resulting from multiple epigenetic and genetic changes. Pharmacological reviews 64: 706-721. 66. Shen J, Chen Y-J, Jia Y-W, Zhao W-Y, Chen G-H, et al. (2017) Reverse effect of curcumin on CDDP-induced drug-resistance via Keap1/p62-Nrf2 signaling in A549/CDDP cell. Asian Pacific Journal of Tropical Medicine 10: 1190-1196. 67. Shi M, Zhang T, Sun L, Luo Y, Liu D-H, et al. (2013) Calpain, Atg5 and Bak play important roles in the crosstalk between apoptosis and autophagy induced by influx of extracellular calcium. Apoptosis 18: 435-451. 68. Shin SW, Kim SY, Park J-W (2012) Autophagy inhibition enhances ursolic acid-induced apoptosis in PC3 cells. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research 1823: 451-457. 69. Siegel RL, Miller KD, Jemal A (2018) Cancer statistics, 2018. CA: A Cancer Journal for Clinicians 68: 7-30. 70. Singh SS, Vats S, Chia AY-Q, Tan TZ, Deng S, et al. (2018) Dual role of autophagy in hallmarks of cancer. Oncogene 37: 1142-1158. 71. Sosa Iglesias V, Giuranno L, Dubois LJ, Theys J, Vooijs M (2018) Drug Resistance in Non-Small Cell Lung Cancer: A Potential for NOTCH Targeting? Frontiers in Oncology 8. 72. Su L-J, Yang C-H, Huang S-F, Yuo Y-L, Hsieh H-C, et al. (2012) Evaluation of the Chinese Medicinal Herb, Graptopetalum paraguayense, as a Therapeutic Treatment for Liver Damage in Rat Models. Evidence-Based Complementary and Alternative Medicine 2012: 15. 73. Sui X, Chen R, Wang Z, Huang Z, Kong N, et al. (2013) Autophagy and chemotherapy resistance: a promising therapeutic target for cancer treatment. Cell Death & Disease 4: e838. 74. Tanida I, Ueno T, Kominami E (2004) LC3 conjugation system in mammalian autophagy. The International Journal of Biochemistry & Cell Biology 36: 2503-2518. 75. Taub M (2016) Cancer drug troglitazone stimulates the growth and response of renal cells to hypoxia inducible factors. Biochemical and Biophysical Research Communications 471: 342-347. 76. To KKW, Wu WKK, Loong HHF (2018) PPARgamma agonists sensitize PTEN-deficient resistant lung cancer cells to EGFR tyrosine kinase inhibitors by inducing autophagy. European Journal of Pharmacology 823: 19-26. 77. TSAI C-L, CHIU Y-M, HO T-Y, HSIEH C-T, SHIEH D-C, et al. (2018) Gallic Acid Induces Apoptosis in Human Gastric Adenocarcinoma Cells. Anticancer Research 38: 2057-2067. 78. Tsapras P, Nezis IP (2017) Caspase involvement in autophagy. Cell Death And Differentiation 24: 1369. 79. Uddin MN, Yin H, Park s-y (2018) Autophagy flux inhibition mediated by celastrol sensitized lung cancer cells to TRAIL‑induced apoptosis via regulation of mitochondrial transmembrane potential and reactive oxygen species. 80. Wang C-W, Klionsky DJ (2003) The molecular mechanism of autophagy. Molecular medicine (Cambridge, Mass) 9: 65-76. 81. Wang H-Y, Zhang Y, Zhou Y, Lu Y-Y, Wang W-F, et al. (2016) Rosiglitazone elevates sensitization of drug-resistant oral epidermoid carcinoma cells to vincristine by G2/M-phase arrest, independent of PPAR-γ pathway. Biomedicine & Pharmacotherapy 83: 349-361. 82. Wang J, Wu GS (2014) Role of autophagy in cisplatin resistance in ovarian cancer cells. The Journal of biological chemistry 289: 17163-17173. 83. Wang Q, Guo Y, Jiang S, Dong M, Kuerban K, et al. (2018) A hybrid of coumarin and phenylsulfonylfuroxan induces caspase-dependent apoptosis and cytoprotective autophagy in lung adenocarcinoma cells. Phytomedicine 39: 160-167. 84. Wood DE, Newcomb EW (2000) Cleavage of Bax Enhances Its Cell Death Function. Experimental Cell Research 256: 375-382. 85. Wood DE, Thomas A, Devi LA, Berman Y, Beavis RC, et al. (1998) Bax cleavage is mediated by calpain during drug-induced apoptosis. Oncogene 17: 1069. 86. Wu Y-T, Tan H-L, Shui G, Bauvy C, Huang Q, et al. (2010) Dual Role of 3-Methyladenine in Modulation of Autophagy via Different Temporal Patterns of Inhibition on Class I and III Phosphoinositide 3-Kinase. Journal of Biological Chemistry 285: 10850-10861. 87. Xia M, Yu H, Gu S, Xu Y, Su J, et al. (2014) P62/SQSTM1 is involved in cisplatin resistance in human ovarian cancer cells via the Keap1-Nrf2-ARE system. 88. Yang Y, Jiang C, Yang Y, Guo L, Huang J, et al. (2018) Silencing of LncRNA-HOTAIR decreases drug resistance of Non-Small Cell Lung Cancer cells by inactivating autophagy via suppressing the phosphorylation of ULK1. Biochemical and Biophysical Research Communications 497: 1003-1010. 89. Yousefi S, Perozzo R, Schmid I, Ziemiecki A, Schaffner T, et al. (2006) Calpain-mediated cleavage of Atg5 switches autophagy to apoptosis. Nature Cell Biology 8: 1124. 90. Yu Y, Zhang X, Tian H, Zhang Z, Tian Y (2018) Knockdown of long non-coding RNA HOTAIR increases cisplatin sensitivity in ovarian cancer by inhibiting cisplatin-induced autophagy. 1396-1401 p. 91. Zhan J-K, Wang Y-J, Li S, Wang Y, Tan P, et al. (2018) AMPK/TSC2/mTOR pathway regulates replicative senescence of human vascular smooth muscle cells. Experimental and therapeutic medicine 16: 4853-4858. 92. Zhang L, Hu J-F, Li G-Q, Xiao X, Su Q (2012) Rosiglitazone Reverses Mitomycin C Resistance in Human Gastric Cancer Cells. The American Journal of the Medical Sciences 343: 382-387. 93. Zhang L, Xu L, Zhang F, Vlashi E (2016) Doxycycline inhibits the cancer stem cell phenotype and epithelial-to-mesenchymal transition in breast cancer. Cell cycle (Georgetown, Tex) 16: 737-745. 94. Zhang Y, Ren S, Liu Y, Gao K, Liu Z, et al. (2017) Inhibition of Starvation-Triggered Endoplasmic Reticulum Stress, Autophagy, and Apoptosis in ARPE-19 Cells by Taurine through Modulating the Expression of Calpain-1 and Calpain-2. International Journal of Molecular Sciences 18. 95. Zhou F, Yang Y, Xing D (2011) Bcl-2 and Bcl-xL play important roles in the crosstalk between autophagy and apoptosis. The FEBS Journal 278: 403-413. 96. Zhou J, Zhang W, Liang B, Casimiro MC, Whitaker-Menezes D, et al. (2009) PPARγ activation induces autophagy in breast cancer cells. The International Journal of Biochemistry & Cell Biology 41: 2334-2342.
摘要: 非小細胞肺癌在化療時常衍生出多重抗藥性,造成臨床治療上之困境,因此極需克服。Rosiglitazone (ROSI)是一種PPAR-γ活化劑,被應用於糖尿病及癌症的治療上,Cisplatin則是目前應用於癌症化療上的第一線用藥。本實驗室近期的研究發現非小細胞肺癌細胞(H460)可透過不同作用機轉產生對抗抑癌藥物ROSI與Cisplatin的高抗藥性。自噬作用是細胞利用溶酶體將有缺失或過多之蛋白或胞器進行降解的一種過程,是細胞自我的保護機制之一,亦被認為是癌細胞產生抗藥性的原因之一。雖然自噬作用可提升癌細胞之抗藥性已在多種癌細胞中被報導,但其對H460細胞多重抗藥性的調控尚未被探討過。因此本論文主要在探討具有細胞保護功能之'自噬作用'是否參調控H460細胞對ROSI及Cisplatin的抗藥性,及其在肺癌治療上之應用。研究的子題目的包括:釐清ROSI與Cisplatin是否會透過提升非小細胞肺癌細胞(H460)之自噬作用來保護細胞之存活並提高細胞之抗藥性;確認ROSI是否會透過活化PPAR-γ啟動PKCδ/JNK-1/BcL-2/Beclin-1訊號路徑來提升自噬作用;並評估具有抑癌功能之石蓮花水萃物(WGP)是否可透過抑制自噬作用的生成來破壞H460細胞對ROSI及Cisplatin之抗藥性;另外,更利用Rapamycin(自噬作用促進劑)加劇ROSI對H460細胞自噬作用的提升,進一步評估過度自噬作用之生成是否可誘發細胞凋亡之發生。實驗中使用的分析方法主要包括,MTT分析法分析細胞存活率,以西方墨點法分析蛋白表現,以Annexin V/PI染色與DAPI染色分析細胞凋亡之發生,以DiOC6染色分析粒線體膜通透性之變化,以及以EMSA分析PPAR-γ之活性。研究結果顯示,ROSI能透過活化PPAR-γ/JNK-1/BcL-2/Beclin-1訊號路徑進而提升自噬作用之生成來促進H460細胞之生長並導致抗藥性的生成。Cisplatin亦能透過提升自噬作用來抑制H460細胞之凋亡,進而產生抗藥性。而自噬作用之抑制劑(3-MA)、PPAR-γ之抑制劑(GW9662)與WGP,均能透過抑制自噬作用來破壞H460細胞之抗藥性,具有成為抗癌藥物之功效。此外,若以Rapamycin加劇ROSI所提升之自噬作用,的確能誘導H460細胞邁向凋亡,破壞細胞對ROSI之抗藥性。整體而言,本論文之重要性在於首次證實自噬作用可以促進H460細胞多重抗藥性的生成;GW9662及WGP可有效抑制被ROSI活化的PPAR-γ/JNK-1/BcL-2/Beclin-1訊號路徑,是兩種新的自噬作用抑制劑;除了抑制自噬作用(以3-MA、GW9662、WGP)外,過度提升自噬作用(以Rapamycin)亦可破壞H460細胞對ROSI之抗藥性,在抗癌藥物之選擇上須特別注意;另外,由於WGP是一副作用低的飲品,又有抑制自噬作用破壞癌細胞抗藥性的功能,未來可考慮做為肺癌化療時的佐劑,用以降低高副作用化療藥物之劑量。
Non-small cell lung cancer (NSCLC) often develops multiple drug resistance during chemotherapy, which has become the biggest obstacle for clinical treatment of lung cancer. Rosiglitazone (ROSI) is a PPAR-γ agonist and has been used in diabetes and cancer treatment. Cisplatin is the first line chemotherapeutic drug for cancer. Our laboratory has recently found that NSCLC cells (H460) have developed higher drug resistance to both ROSI and Cisplatin, via different working mechanisms. Autophagy is a self-eating process to degrade defect or excessive proteins or organelles to protect cell from extreme environmental changes. It has been indicated to involve in the drug resistance of many cancer cells. The role of autophagy in regulating of multidrug resistance of H460 cells was still unclear. The primary goal of the study was to know if autophagy contributes to the drug resistances of H460 cells to ROSI and cisplatin, and its application in lung cancer therapy. The specific aims of the study included: to clarify if ROSI and cisplatin act through autophagy to promote the growth (or survival) and drug resistance of H460 cells; to confirm if ROSI act through PPAR-γ to initiate the PKCδ/JNK-1/BcL-2/Beclin-1 signaling pathway to stimulate autophagy; to know if water extract of Graptopetalum paraguayense leaves (WGP) inhibits autophagy to break drug resistance of H460 cells to ROSI and cisplatin; and to clarify if rapamycin (autophagy activator) aggravates ROSI-induced autophagy to trigger the apoptosis of H460 cells. The techniques applied in the study included, the MTT assay, Western blotting, Annexin V/PI staining, DAPI staining, DiOC6 staining and EMSA. The results showed that ROSI activated the PPAR-γ/JNK-1/BcL-2/Beclin-1 signaling pathway to stimulate autophagy, which in turn promoted the growth and drug resistance of H460 cells. Cisplatin also stimulated autophagy to inhibit apoptosis of H460 cells and lead to drug resistance. Autophagy inhibitor (3-MA), PPAR-γ inhibitor (GW9662) and WGP, all inhibited autophagy to break drug resistance of H460 cells and revealed a potential to become anticancer drugs. Rapamycin-aggravated autophagy in ROSI-treated H460 cells can indeed trigger apoptosis and break drug resistance to ROSI. In overall, the major contributions of this study were to demonstrate for first time that autophagy played a critical role in the regulation of multiple drug resistance of H460 cells; GW9662 and WGP can block ROSI-activated PPAR-γ/JNK-1/BcL-2/Beclin-1 signaling pathway to server as new autophagy inhibitors; autophagy inhibition (by 3-MA, GW9662 or WGP) and excessive induction of autophagy (by rapamycin) can both break drug resistance of H460 cells to ROSI, a critical concern for anticancer drug selection; furthermore, since WGP is safe to drink and can block the anticancer drug-induced autophagy to break drug resistance of H460 cells, it may be considered to be used as an adjuvant during chemotherapy to lower down dose of the anticancer drug applied and adverse side effects.
URI: http://hdl.handle.net/11455/97729
文章公開時間: 10000-01-01
Appears in Collections:生命科學系所

文件中的檔案:

取得全文請前往華藝線上圖書館



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.